IMMUNOLOGY MARKET ANALYSIS

Key Developments

• On May 22, 2024, Biogen Inc, an American multinational biotechnology company, and Human Immunology Biosciences, a privately-held clinical-stage biotechnology firm specializing in tailored treatments for individuals with severe immune-mediated diseases (IMDs), announced that both companies had signed definitive agreement. According to the agreement, Biogen will purchase HI-Bio for an initial sum of US$ 1.15 billion, with the potential for additional milestone payments totaling up to US$ 650 million.
• On May 15, 2024, Blackstone, a investment management company, introduced Uniquity Bio, a clinical-stage drug development company concentrating on immunology and inflammation, within the Blackstone Life Sciences (“Blackstone”) portfolio. Uniquity Bio emerges from secrecy with the FDA's approval of its Phase 2 investigational new drug (“IND”) application for solrikitug, a monoclonal antibody aimed at TSLP, and is set to receive up to US$300 million in funding from Blackstone to progress the asset across various indications.
• In April 2023, Merck, recognized as MSD, a multinational science and technology company, and Prometheus Biosciences, Inc., a biopharmaceutical company, announced that both companies had signed a definitive agreement. According to this agreement, Merck, via a subsidiary, will purchase Prometheus for US$ 200.00 per share in cash.
• In November 2022, Genmab, a biotech company, and BioNTech, a Germany-based biotechnology company, collaborated to develop the DuoBody-PD-L1x4-1BB (GEN1046) monoclonal antibody for Phase 1/2 trials in solid tumors and Phase 2 trials in non-small cell lung cancer
• In October 2022, the U.S. FDA granted approval for the combination of durvalumab (Imfinzi) and tremelimumab (Imjudo) for individuals with unresectable hepatocellular carcinoma, the predominant form of liver cancer